Global Dementia and Movement Disorders Market: Overview
Dementia is mainly recognized as mental illnesses, which can lead to degeneration of the capability to remember or think in an individual. As a result, the syndrome is only treated symptomatically. However, in several cases movement disorders are also observed, for instance, Parkinson’s are recognized to be a medium for dementia. Based on the research around 80% of individuals with Parkinson’s or other movement syndromes are likely to develop cognitive issues.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Global Dementia and Movement Disorders Market: Growth Factors
Global dementia and movement disorders market is driven by a quickly expanding geriatric populace highly susceptible to different neurodegenerative syndromes. In addition to this, other major aspects which are slated to optimistically impact the market are a frequent partnership among pharmaceutical companies, research organizations, drug and device manufacturing firms, and medical institutes. These collaborations have resulted in tremendous R&D efforts aimed at the discovery of effective treatment options for the condition of dementia & movement disorders.
The global market is, however, affected by many restraints that threaten to obstruct its expansion in the coming years. A key restraining aspect is a limited knowledge regarding brain mechanisms as well as the various neurodegenerative syndromes. Furthermore, management solutions for neurological disorders, the absence of comprehensive therapeutics, drug failures in late-stage clinical trials, lengthy approval time for drugs, rigid regulatory requirements and devices act as deterrents to the development of the market for global dementia and movement disorders market.
Global Dementia and Movement Disorders Market: Segmentation
Global dementia and movement disorders market can be classified in terms of drugs utilized for movement disorders & progressive dementia with other neurological abnormalities and treatment of progressive dementia. Amongst these, the division of drugs majorly used in the treatment of progressive dementia is categorized as diseases based therapeutics in progressive dementia and drugs for progressive dementia. Furthermore, the division of drugs utilized with other different neurological abnormalities to treat progressive dementia is fragmented into disease-based therapeutics with other neurological abnormalities and drugs with other neurological abnormalities for progressive dementia under progressive dementia. Also, the division of drugs utilized for treating movement disorders is divided into diseases based therapeutics and drugs for movement disorders in movement disorders.
Global Dementia and Movement Disorders Market: Regional Analysis
North America is likely to account for a momentous share in the global market, driven mainly by the high occurrence rate of the neurodegenerative syndrome, also resulting in a large number of individuals living with limited mobility. With considerably aging inhabitants, the number of individuals afflicted by different neurological syndromes has augmented. The market for dementia and movement disorders in Europe is likely to be the strong contender in the overall development and is likely to be propelled by similar aspects.
The Asia Pacific is projected to register significant expansion rate in the coming future with a growing number of responsiveness programs particularly initiated by private as well as public healthcare institutions. A huge population base, which includes geriatrics and increasing healthcare insurance coverage is likely to be responsible for the anticipated expansion of the Asia Pacific region for global dementia and movement disorders market.
Global Dementia and Movement Disorders Market: Competitive Players
Some of the most important market players in the global dementia and movement disorders market are Valeant Pharmaceutical International, Pfizer, Hoffmann-La Roche, Novartis AG, AstraZeneca GmbH, Sanofi S.A., and Merck & Co., among others.
Global Dementia and Movement Disorders Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets